
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
Keywords: سرطان غیر سلول کوچک ریه; Non-small cell lung cancer; Epidermal growth factor receptor; Gefitinib; Pemetrexed; Phase II study; First-line treatment;